SOOLANTRA

Patient Savings Card Makes Treatment More Affordable

ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS

FOR EACH PRESCRIPTION^†‡

^†Restrictions apply.
See patient savings card for details.

^‡Galderma CareConnect is only available for commercially insured or uninsured patients. Patients who are enrolled in a government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CareConnect Patient Savings Card.

Thank You for Choosing SOOLANTRA Cream

Your representative will be contacting you to schedule a time to deliver your patient savings cards.

Full Name* Full name is required

Address* Address is required

City* City is required

State* This field is required

Zip Code* This field is required

Email Address* This field is required

Phone Number Phone number is required

Best Way To Contact You* Preferred contact method is required

*Required field

Patient Savings Card Makes Treatment More Affordable

ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS

FOR EACH

PRESCRIPTION^†‡

^†Restrictions apply. See patient savings card for details.

^‡Galderma CareConnect is only available for commercially insured or uninsured patients.Patients who are enrolled in a government-run or government-sponsored health care plan with a pharmacy benefit are not eligibl, e to use the Galderma CareConnect Patient Savings Card.

START AND STAY WITH SOOLANTRA^® CREAM FOR CLEARER RESULTS^1-4a

60% MORE subjects were rated clear^§ vs MetroCream^® (metronidazole) Topical Cream (P<0.001)^1-3

NEARLY 1 OUT OF 3 SUBJECTS REMAINED CLEAR^§ or almost clear at 1 year⁴

CETAPHIL^® MOISTURIZING CREAM was the basis for the vehicle³

Thank You for Choosing Soolantra Cream

Your representative will be contacting you to schedule a time to deliver your patient copay cards.

Full Name* Full name is required

Address* Address is required

State* This field is required

Zip Code* This field is required

Email Address* This field is required

Phone Number Phone number is required

Best Way To Contact You* Preferred contact method is required

*Required field

^§CLEAR is defined as IGA score of 0 according to the IGA (Investigator Global Assessment) scale, which is commonly used by dermatologists.

^aA phase 3, investigator-blinded, multicenter, randomized, parallel-group study comparing the efficacy and safety of SOOLANTRA Cream, 1% once daily with metronidazole 0.75% cream twice daily in 962 subjects 18 years of age and older with moderate to severe papulopustular rosacea (IGA score of 3 or 4) over a 16-week treatment period (Part A). A total of 757 successfully treated subjects, rated clear or almost clear (IGA score of 0 or 1) continued to the 36-week extension evaluating the relapse after a treatment-free period (Part B).^3,4

In Part B, subjects were followed every 4 weeks for up to 36 additional weeks (Weeks 16-52). If relapse (defined as IGA score of ≥2 [mild, moderate, or severe]) occurred, subjects were re-treated with the same treatment they had received during the initial 16-week study (Part A). Re-treatment was stopped after the exact number of days it took for IGA to return to an IGA score of ≤1 (clear or almost clear), with a maximum duration of re-treatment of 16 consecutive weeks to mimic the Part A treatment duration. Several re-treatment periods were permitted.^3,4

IMPORTANT SAFETY INFORMATION

Indication: SOOLANTRA^® (ivermectin) Cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use.

Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence ≤1%) included skin burning sensation and skin irritation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Click here for full Prescribing Information.

References 1. Taieb A, Ortonne JP, Ruzicka T, et al; Ivermectin Phase III Study Group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015:172(4):1103-1110. 2. Deeks ED. Ivermectin: a review in rosacea. Am J Clin Dermatol. 2015;16(5):447-452. 3. Data on file. Galderma Laboratories, L.P. 4. Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016:30(5):829-836.